Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
posted on
Aug 04, 2020 09:21PM
,,,I would probably add to that the all important fact that the low share price only benefits one group of people,,,,,,,,yep,,you guessed it,,,,,it is very odd that a potential blockbuster drug with good safety history has no interest from any side of this equation,,,very odd indeed,,,,,,,,,,,,and with break thru therapy designation to boot,,,,,,think about it,,,,,,,odd,,very odd!..so odd one would think it is intentional,,,,